



Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums

Paris and Boston, January 21, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its financial calendar for the 2026 fiscal year as well as the resumption of its participation in investor conferences.

Events	Date
2025 Annual Results	April 9, 2026
Q1 2026 Sales	April 16, 2026
2026 Annual General Meeting	June 4, 2026
Q2 2026 Sales	July 21, 2026
2026 Half-Year Results	October 8, 2026
Q3 2026 Sales	October 20, 2026

Note: These dates are indicative and subject to adjustment.

After a 2025 fiscal year marked by the successful restructuring of its balance sheet and the implementation of structuring strategic partnerships, Mauna Kea Technologies wishes to share its progress and growth prospects more regularly with the financial community.

In this context, Management will participate in the following events in the first half of 2026:

- **Allinvest Securities Biomed Forum:** January 29, 2026 – Paris
- **TP ICAP Midcap Annual Conference:** May 6 and 7, 2026 – Paris
- **Portzamparc Mid & Small Caps:** June 24 and 25, 2026 – Paris
- *Other conferences, particularly international ones, will be announced later.*

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “In 2025, we voluntarily put our participation in investor conferences on hold in order to focus on our financial restructuring. Building on the current momentum and the significant progress made, we have decided to fully resume communication in 2026. We wish to meet again regularly with investors, analysts, and partners, both in France and internationally, in order to present our strategy, our progress, and the Company’s prospects to them. We are already available for individual or group meetings. You can contact us at the address investors@maunakeatech.com.”



About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Mauna Kea Technologies

investors@maunakeatech.com

NewCap - Investor Relations

Thomas Grojean

+33 (0)1 44 71 94 94

maunakea@newcap.eu

Disclaimer

This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the *Autorité des marchés financiers* (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.